28 related articles for article (PubMed ID: 25567592)
21. Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions.
Roszkowski K; Furtak J; Zurawski B; Szylberg T; Lewandowska MA
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834917
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment.
July J; Patricia D; Gunawan PY; Setiajaya H; Ginting TE; Putra TP; Wuisan Z; Budhiarko D; Masykura N; Prayogi G; Utomo AR; Tandean S; Loe ML
Pan Afr Med J; 2020; 36():309. PubMed ID: 33282092
[TBL] [Abstract][Full Text] [Related]
23. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.
Capper D; Mittelbronn M; Meyermann R; Schittenhelm J
Acta Neuropathol; 2008 Feb; 115(2):249-59. PubMed ID: 17965865
[TBL] [Abstract][Full Text] [Related]
24. [IDH1 mutation and MGMT expression in astrocytoma and the relationship with prognosis after radiotherapy].
Jiang M; Dong X; Li J; Li J; Qi J
Zhonghua Bing Li Xue Za Zhi; 2014 Oct; 43(10):668-72. PubMed ID: 25567592
[TBL] [Abstract][Full Text] [Related]
25. Gliomatosis cerebri: Prognosis based on current molecular markers.
Maharaj MM; Phan K; Xu J; Fairhall J; Reddy R; Rao PJV
J Clin Neurosci; 2017 Sep; 43():1-5. PubMed ID: 28539209
[TBL] [Abstract][Full Text] [Related]
26. Supratentorial grade II astrocytoma: biological features and clinical course.
Wessels PH; Weber WE; Raven G; Ramaekers FC; Hopman AH; Twijnstra A
Lancet Neurol; 2003 Jul; 2(7):395-403. PubMed ID: 12849117
[TBL] [Abstract][Full Text] [Related]
27.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
28.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
